We then categorized the meningiomas cases based on co-expression of all three markers: PD-L1 (high/low, median = 0.08%), NFKB2 (high/low), and CA9 (positive/negative) into 8 subgroups (Fig. 3E). This evidence concerns the gene CA9 and meningioma.